Somatic Cell Reprogramming for Autologous Pluripotency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating pluripotent stem cells are controversial and involve embryonic sources, fetal tissue, or interspecies mixing, leading to immune rejection risks and slowed research and therapeutic applications.
Innovation Solution
Engineered somatic cells with endogenous pluripotency genes linked to selectable markers are used to reprogram cells into a less differentiated state, allowing for the generation of autologous pluripotent cells without embryos or nuclear transfer technology, using agents that alter chromatin structure or introduce pluripotency genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If embryonic stem cells or fetal tissue are used to generate pluripotent cells, then pluripotency is achieved, but ethical controversy and immune rejection risks increase
Solution Approach 1:
The patent creates autologous pluripotent cells by reprogramming the patient's own somatic cells through viral transduction of pluripotency factors (Oct4, Sox2, Klf4, c-Myc). This copying approach generates cells identical to the patient's genetic material, eliminating immune rejection risks while avoiding ethical controversies associated with embryonic or fetal sources
Solution Approach 2:
The patent fundamentally changes the source parameter from embryonic/fetal tissues to adult somatic cells. By inducing expression of specific transcription factors in differentiated cells, the patent transforms their differentiation state back to pluripotency, thereby achieving reliable pluripotent cell generation without the harmful associations of traditional methods
2Reliability
If somatic cell nuclear transfer is used to generate pluripotent cells, then pluripotency is achieved, but technical complexity and time consumption increase
Solution Approach 1:
The patent extracts and eliminates the complex nuclear transfer procedure entirely. Instead of removing nuclei, fusing cells, and managing enucleated oocytes, the patent directly introduces pluripotency factors into somatic cells using viral vectors, simplifying the process to a single transduction step followed by culture
Solution Approach 2:
The patent introduces viral vectors as intermediaries to deliver pluripotency factors into somatic cells. This intermediary approach replaces the complex mechanical and biological processes of nuclear transfer with a streamlined molecular delivery system, significantly reducing technical complexity
3Reliability
If animal oocytes are used for nuclear transfer, then pluripotent cells can be generated, but immune rejection risks increase due to non-human mitochondria and viruses
Solution Approach 1:
The patent uses the patient's own somatic cells as templates to create autologous pluripotent cells through viral transduction. This copying process maintains identical human genetic material and eliminates all non-human biological components, ensuring complete compatibility with the patient's immune system
Solution Approach 2:
The patent converts the limitation of somatic cells (differentiated state) into a benefit by using viral vectors to reprogram them back to pluripotency. This approach transforms what was previously a dead end into a valuable source of patient-specific pluripotent cells without requiring animal materials
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the generation of autologous pluripotent cells, reducing immune rejection risks and providing a non-controversial source for cell therapy, with the ability to differentiate into various cell types, thus overcoming the limitations of existing methods.
Implementation Method 1
contacting the cells with an agent which alters chromatin structure
Data Source
AI summary
The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.